(PharmaNewsWire.Com, August 28, 2017 ) The Asia Pacific Nuclear medicine Radiopharmaceuticals Industry is estimated at USD 855 Million in 2015 and is expected to reach USD 1.67 billion by 2020, growing at a CAGR of 14.3%. Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.
Increasing incidence of chronic diseases such as cancer and cardiac ailments, advancements in technology, increasing demand for SPECT and PET applications along with the growing public awareness for healthcare are fuelling the growth of the market. Further, new developments such as Integration of X ray tomography (CT) into SPECT provide an excellent diagnostic tool in medical imaging and are considered to be a driving factor for the growth of the market. Strict regulatory framework poses a potential hurdle to translational research and clinical investigations. Reimbursement issues are also blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are the key factors restraining the Asia-Pacific nuclear medicine Radioisotopes market.
Diagnostic Radioisotopes is the dominating segment and account for around 90 % of the radiopharmaceuticals market while therapeutic radioisotopes contribute 10% of the market. Based on type of radioisotopes the market is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Fluorine-18, Iodine (I-123), Rubidium-82 (RB-82) and others. The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcomes of these tracers have been gaining the business interest of major research institutes and PET isotope players in the recent times. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market.
Some of the key players influencing the Asia-Pacific nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact: Abhishek Shukla Sales Manager (International Business Development) Market Data Forecast Direct Line: +1-888-702-9626 Mobile: +91 998 555 0206 Mail: abhishek@marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
